Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 1, 2026
Valion Bio, Inc. (VBIO)
A forensic read on Valion Bio, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-2.2
Distress distance
Clean
Earnings quality
4
Forensic signals
-52.9%
ROE
-33.7%
Revenue growth
The financial-health reading above compares this company's equity at BOOK value, not at what the market currently pays for it — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Valion Bio, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -2.2, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+182.3%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +182.3% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. This is the third straight fiscal year of building accruals — a multi-year streak is a materially stronger tell than a single year's move. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 31% of net operating assets, against an accruals ratio of 182.3%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
57d DSO
FY2023→FY2024
Receivables vs revenue.Days sales outstanding moved from 44 to 57 days FY2023→FY2024 (receivables -60% vs revenue -34%). Receivables are creeping up relative to sales. Across FY2022–FY2024 the day count ran 20 → 44 → 57 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter.
n/m (stock split)
FY2021–FY2024
Share count (stock split).Diluted share count changed -92% over the last 3 years to FY2024, but that includes a large one-time change around FY2022 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw -56.5%/yr figure isn't a real buyback/dilution read here.
29% of rev
Key fundamentals
Latest Revenue$780,000.00
Revenue Growth YoY-33.7%
Revenue CAGR (3yr)-14.7%
Net Margin-725.0%
Free Cash Flow-$7.0M
Return on Equity-52.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Valion Bio, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 1, 2026. Forensic signals flag probability, not certainty.
Valion Bio, Inc. (VBIO) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
FY2024
Stock-based comp load.Stock-based compensation ran 29% of revenue in FY2024 — about $0.80 per diluted share. It is a real cost, but it is not a cash cost — no cash left the business, which is why operating cash flow adds it back. Where a compensation charge lands instead is the share count, and this filer's count is not on file in enough years to say how the count moved.